In a presentation at the ASCO Annual Meeting, Dr. Andrew Himelstein, MD, FACP of the Helen F. Graham Cancer Center & Research Institute, presented the results of a trial evaluating Zoledronic Acid (Zometa) at a dosing schedule of every 12 weeks as opposed to the current standard of care of every 4 weeks. The trial included [...]
It is known that Zoledronic acid (ZA) reduces the risk of developing skeletal-related events (SRE) which are caused by bone metastasis in prostate cancer (PCa). ZA also improves the quality of life (QOL). ZA has become a standard supportive therapy for men with prostate cancer who have bone metastasis. The big unknown is when should [...]
Docetaxel is the only globally approved first-line chemotherapy for the treatment of castrate resistant prostate cancer. Yhe universal truth is that all men taking docetaxel will become refractory to the treatment. Zoledronic acid (ZA) is the most commonly used member of nitrogen-containing bisphosphonate family. By itself it has anti-tumor activity, including in prostate cancer. In [...]
Chemotherapy using docetaxel remains an important therapy, despite the newly approved drugs, to treat hormone refractory prostate cancer. Chemotherapy improves survival, however, all men taking it will eventually become refractory to the treatment. Zoledronic acid (ZA) is the most potent member of nitrogen-containing bisphosphonate family and has anti-tumor activity in prostate cancer. In a study, [...]
Men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) will eventually develop debilitating pain that impacts daily functioning and diminishes their quality of life. Based on prior studies, including a phase III trial, the superiority of denosumab over zoledronic acid (ZA) in delaying or preventing skeletal-related events (pathological fracture, radiation or surgery to the [...]
Men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) will often have debilitating pain that impacts every aspect of their daily functioning thus significantly diminishing their quality of life (QoL). Finding the best drug or treatment to control the pain will allow men to have a more complete and fulfilling life as well as [...]
From: the 2014 ASCO GU Meeting Abstract No: 35 Researchers have found in a randomized controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC) the use of the treatment denosumab was superior to the more commonly used zoledronic acid (ZA) for reducing skeletal-related events (SRE). SREs are defined as a pathological fracture, surgery or [...]
A recent study conducted at the Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA by the Section of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA, evaluated the efficacy of the timely use of zoledronic acid (ZA) on clinical outcomes and health care utilization in men with bone-metastatic prostate [...]
Pamidronate and zoledronic acid (bisphosphonates) are a mainstay in the treatment of men with advanced prostate cancer as well as for breast cancer survivors for the prevention of skeletal-related events (SREs). There have been many clinical trials comparing the efficacy and side effect profiles between pamidronate and zoledronic acid among men with advanced prostate cancer. [...]
